BoA Merrill Lynch has upgraded CSL to Buy from Neutral with a target price of $71.25 (currently $64.66)

BoA Merrill Lynch has upgraded CSL to Buy from Neutral with a target price of $71.25 (currently $64.66). The broker believes the plasma group can grow earnings at a higher-rate than consensus given increasing scale in plasma, entry in Japan and a new product for the US. Although CSL trades at a high PE of 25.97, it has consistently justified this with solid demand and earnings growth. The broker has also tipped CSL to launch a $900m-plus share buyback later this year given strong cash flow generation and the need to keep its leverage ratio within range of 0.7-1.2 times.


2 topics

Livewire News brings you a wide range of financial insights with a focus on Global Macro, Fixed Income, Currencies and Commodities.

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.